ZYME Earnings Prediction
The chart below shows how ZYME performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ZYME sees a -1.68% change in stock price 10 days leading up to the earnings, and a +3.46% change 10 days following the report. On the earnings day itself, the stock moves by +0.31%. This data can give you a slight idea of what to expect for the next quarter's release.
ZYME Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
ZYME Earnings Analysis
Zymeworks Inc Corporation (ZYME.O) Earnings Conference Call
Positive
Zanidatamab Approval Milestone: Zymeworks reported the approval of zanidatamab, marking a significant milestone in their clinical development strategy.
Partnership Revenue Success: The company earned over $45 million from partnerships in the past year, showcasing the strength of their collaborations.
Research Milestone Achievement: Zymeworks achieved a $14 million research milestone from GSK, indicating the long-term value of their innovative approach.
Successful Product Commercialization: Ziihera, launched by Jazz, achieved net product sales of $1.1 million in Q4 2024, reflecting successful commercialization efforts.
Strong Financial Position: The company has a strong financial position with $324.2 million in cash resources, providing a runway into the second half of 2027.
Pipeline Advancement: Zymeworks is advancing its pipeline with promising candidates like ZW251, which is prioritized for IND submission and Phase 1 trials.
Expansion into Autoimmune Diseases: The company is expanding its focus into autoimmune and inflammatory diseases, leveraging their existing technology and expertise.
Clinical Trial Initiation: Zymeworks has initiated two global Phase 1 clinical trials for ZW171 and ZW191, demonstrating progress in their clinical development efforts.
Negative
Earnings Miss Report: Zymeworks Inc. misses on earnings expectations, reporting an EPS of $-0.31 against expectations of $0.01.
Net Loss Increase: The net loss for the year ended December 31, 2024, was $122.7 million, an increase from $118.7 million in 2023, primarily due to a $17.3 million noncash impairment charge.
Operating Expenses Overview: Operating expenses were $213.4 million for the year, a slight increase from $214.1 million in 2023, despite a decrease in R&D and G&A expenses.
Discontinuation of Clinical Program: The company decided to discontinue the zanidatamab zovodotin clinical development program, leading to a significant impairment charge.
Cash Resource Decline: Cash resources decreased to $324.2 million as of December 31, 2024, down from $456.3 million in 2023, indicating a reduction in financial stability.
Phase 1 Study Delay: The company has paused preparations for the commencement of Phase 1 studies for ZW220, indicating potential delays in development.
Increased Compensation Expenses: Stock-based compensation expenses increased due to new grants, which may indicate higher operational costs in the future.
ZYME FAQs
How does ZYME typically perform around its earnings report dates?
Is Zymeworks Inc (ZYME) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ZYME Earning Call Sentiment
Zymeworks Inc. (NYSE:ZYME) Q4 2024 Earnings Call Transcript
ZYME.O
-1.07%Positive
The earnings call reveals disappointing financial results, with a significant EPS miss and increased net loss. Despite optimistic guidance and strategic prioritization of ZW251, management's unclear responses on trial delays raise concerns. The cash burn and decreased cash resources further weigh on sentiment. While share repurchases and potential milestone payments offer some positives, they are overshadowed by the financial performance and uncertainties, leading to a likely negative market reaction.
